Prognostic value of systemic immune-inflammatory index in survival outcome in gastric cancer: a meta-analysis

Abstract

Background: In recent years, many studies have reported that the systemic immune-inflammatory index (SII) can be used to predict the prognosis of cancer patients; however, this finding remains controversial in gastric cancer (GC). Therefore, the purpose of this study was to systematically and comprehensively probe the prognostic role of SII in GC. Methods: Relevant publications were extracted from PubMed, EMBASE, Cochrane Library databases, and WANFANG DATA (Chinese database). The included studies had patients with pathologically confirmed GC and long-term follow-up data. The patient's outcome was death, recurrence, or status at the end of follow-up. The studies included randomized controlled tests, case-control studies, or cohort studies using a multivariate proportional hazard model adjusted for survival outcomes. Cochran's Q test and Higgins' I-squared statistic were performed to assess heterogeneity. Publication bias was assessed by visual inspection of a Begg's funnel plot. Results: A total of 6,925 patients in 11 studies were included. The pooled hazard ratio (HR) indicated that a higher SII value was significantly associated with worse overall survival (OS) [HR: 1.53, 95% confidence interval (CI): 1.27-1.83] and worse disease-free survival (DFS) (HR: 1.57, 95% CI: 1.24-1.97) in GC patients. In the subgroup analysis, the HR was 1.72 (95% CI: 1.51-1.95) and 1.27 (95% CI: 0.96-1.67) in the group of patients aged <59 and ≥59 years, respectively. Conclusions: The pooled HR indicates that a higher SII in younger patients with GC predicts a poor prognosis. In elderly patients with GC, the prognostic role of SII needs further research.

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

“…Recently, it has been reported that the SII sore is of prognostic value in many malignant tumor types including hepatocellular carcinoma [ 37 ], gastric cancer [ 38 ], colorectal cancer [ 39 ], and urological and gynecological tumors [ 13 , 40 ]. Given that RCC is an inflammatory disease, the investigation of the SII score seems to be of particular interest in patients treated with immune checkpoint inhibitors.…”

Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis

“…A meta-analysis that included 2,796 patients reported that a high SII was associated with poor prognosis in patients with hepatocellular carcinoma (44). Fu et al observed that a high SII was significantly associated with poor OS and DFS in patients with gastric cancer (45). Huang et al also reported that a high SII was associated with poor OS, PFS, and CSS in patients with urologic cancers (48).…”

“…Recent meta-analyses have investigated the prognostic role of SII in many cancer types, including hepatocellular ( 44 ), gastric ( 45 ), breast ( 46 ), and colorectal cancer ( 47 ). A meta-analysis that included 2,796 patients reported that a high SII was associated with poor prognosis in patients with hepatocellular carcinoma ( 44 ).…”

“…Fu et al. observed that a high SII was significantly associated with poor OS and DFS in patients with gastric cancer ( 45 ). Huang et al.…”

Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients

“…Li et al showed that an elevated preoperative SII was significantly associated with worse survival outcomes and adverse pathological features in patients with bladder cancer based on a meta-analysis of 7087 patients [ 49 ]. Fu et al reported that a higher SII value was significantly associated with worse OS and DFS in gastric cancer in a meta-analysis of 11 studies [ 50 ]. Another meta-analysis of 3180 patients revealed that a high SII was independently associated with poor survival outcomes in patients with renal cell carcinoma [ 51 ].…”